BRIEF-Kymera Therapeutics Announces Third Quarter 2024 Financial Results

Reuters
31 Oct 2024

Oct 31 (Reuters) - Kymera Therapeutics Inc :

* KYMERA THERAPEUTICS ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

* KYMERA THERAPEUTICS: TO ONLY ADVANCE KT-333 (STAT3) AND KT-253 (MDM2) BEYOND PHASE 1 WITH A PARTNER

* KYMERA THERAPEUTICS INC: TO SHIFT FOCUS AND RESOURCES FROM ONCOLOGY TO ITS EXPANDING IMMUNOLOGY PIPELINE

* KYMERA THERAPEUTICS INC: KT-295, NEW TYK2 DEGRADER, SELECTED AS DEVELOPMENT CANDIDATE TO ADVANCE INTO PHASE 1 CLINICAL TRIAL IN H1 2025

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10